Investor contact
For investor related questions, please email
investors@aclaristx.com
Media contact
& resources »

Press Releases

Press Releases

May 8, 2019
Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments
May 1, 2019
Aclaris Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019
April 25, 2019
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis
April 24, 2019
Aclaris Therapeutics Announces Issuance of a Patent Covering the use of Ruxolitinib and its Deuterated Forms to Treat Alopecia Areata
March 27, 2019
Aclaris Therapeutics to Attend Upcoming Investor Conference
March 18, 2019
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments
March 8, 2019
Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 18, 2019
February 28, 2019
Aclaris Therapeutics Receives European Approvals of ESKATA® (hydrogen peroxide) cutaneous solution, 685 mg
February 19, 2019
Aclaris Therapeutics to Present Scientific Posters at the 77th Annual Meeting of the American Academy of Dermatology
January 2, 2019
Aclaris Therapeutics to Attend Upcoming Investor Conferences
Load More »